Marshall, V.L. and Grosset, D.G. (2004) GPI-1485 Guilford. Current Opinion in Investigational Drugs, 5(1), pp. 107-112. (PMID:14983983)
Full text not currently available from Enlighten.
Abstract
GPI-1485 is a neuroimmunophilin ligand that binds to FK-506-binding proteins and is under development by Guilford for the potential treatment of erectile dysfunction following nerve injury during prostate resection and Parkinson's disease. In August 2002, phase II clinical trials investigating GPI-1485 for Parkinson's disease commenced, and in November 2003, further phase II trials commenced for post-prostatectomy erectile dysfunction.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Grosset, Professor Donald |
| Authors: | Marshall, V.L., and Grosset, D.G. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Psychology & Neuroscience |
| Journal Name: | Current Opinion in Investigational Drugs |
| Publisher: | Pharma Press Ltd |
| ISSN: | 1472-4472 |
| ISSN (Online): | 2040-3429 |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details